Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Picard

Showing results (251-260 of 269) with videos related to

Pageof 27
Sort By:
Journal of Medicinal Chemistry|March 4, 1994
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activityD R Sliskovic, B R Krause, J A Picard, et al.
Journal of Medicinal Chemistry|January 1, 1991
Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductaseB D Roth, T M Bocan, C J Blankley, et al.
Journal of Medicinal Chemistry|January 29, 2000
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitorsP M O'Brien, D F Ortwine, A G Pavlovsky, et al.
Journal of Medicinal Chemistry|October 29, 1993
Inhibitors of acyl-Coa:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agentsB K Trivedi, A Holmes, T L Stoeber, et al.
Journal of Medicinal Chemistry|May 29, 1992
Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-onesD R Sliskovic, C J Blankley, B R Krause, et al.
The British Journal of Dermatology|June 22, 2019
Does surgery of lymphatic malformations lead to an increase in superficial lymphangiectasia? A retrospective study of 43 patientsA Schreiber, V Soupre, N Kadlub, et al.
Diabetes, Obesity & Metabolism|September 10, 2014
Physiological and pathophysiological implications of lipid sensing in the brainA Picard, V S Moullé, C Le Foll, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 4, 2022
Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancerS Sumodhee, L Guo, L Bouhlel, et al.
Journal of Medicinal Chemistry|December 20, 1996
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented dietsH T Lee, D R Sliskovic, J A Picard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2019
Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanomaC Bence, V Hofman, E Chamorey, et al.
Pageof 27

Showing results (251-260 of 269) with videos related to

Sort By:
Pageof 27
Journal of Medicinal Chemistry|March 4, 1994
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activityD R Sliskovic, B R Krause, J A Picard, et al.
Journal of Medicinal Chemistry|January 1, 1991
Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductaseB D Roth, T M Bocan, C J Blankley, et al.
Journal of Medicinal Chemistry|January 29, 2000
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitorsP M O'Brien, D F Ortwine, A G Pavlovsky, et al.
Journal of Medicinal Chemistry|October 29, 1993
Inhibitors of acyl-Coa:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agentsB K Trivedi, A Holmes, T L Stoeber, et al.
Journal of Medicinal Chemistry|May 29, 1992
Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-onesD R Sliskovic, C J Blankley, B R Krause, et al.
The British Journal of Dermatology|June 22, 2019
Does surgery of lymphatic malformations lead to an increase in superficial lymphangiectasia? A retrospective study of 43 patientsA Schreiber, V Soupre, N Kadlub, et al.
Diabetes, Obesity & Metabolism|September 10, 2014
Physiological and pathophysiological implications of lipid sensing in the brainA Picard, V S Moullé, C Le Foll, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 4, 2022
Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancerS Sumodhee, L Guo, L Bouhlel, et al.
Journal of Medicinal Chemistry|December 20, 1996
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented dietsH T Lee, D R Sliskovic, J A Picard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2019
Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanomaC Bence, V Hofman, E Chamorey, et al.
Pageof 27